N-Nitroso Fedratinib Impurity 1
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Fedratinib is used to treat adults with certain types of myelofibrosis (MF; a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production). Fedratinib is in a class of medications called kinase inhibitors.N-Nitroso Fedratinib Impurity 1 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
N-Nitroso Fedratinib Impurity 1 CAS NO:NA Chemically represented as N-(Tert-butyl)-3-((5-methyl-2-(nitroso(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl) (nitroso) amino) benzenesulfonamide .Synchemia is the leading manufacturing and exporter of N-Nitroso Fedratinib Impurity 1.We supply N-Nitroso Fedratinib Impurity 1 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143044 |
| CAS No | NA |
| Mol.F. | C19H22N4O4 |
| Mol.Wt. | 370.41 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143045 |
| CAS No | NA |
| Mol.F. | C12H13N3O3 |
| Mol.Wt. | 247.25 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143046 |
| CAS No | NA |
| Mol.F. | C14H19N3O4 |
| Mol.Wt. | 293.32g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143047 |
| CAS No | NA |
| Mol.F. | C14H19N3O4 |
| Mol.Wt. | 293.32 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143048 |
| CAS No | NA |
| Mol.F. | C19H21N3O4 |
| Mol.Wt. | 355.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143049 |
| CAS No | NA |
| Mol.F. | C19H29N3O4 |
| Mol.Wt. | 363.46 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143050 |
| CAS No | NA |
| Mol.F. | C24H23N3O4 |
| Mol.Wt. | 417.47 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143051 |
| CAS No | NA |
| Mol.F. | C19H22N2O5 |
| Mol.Wt. | 358.39 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143052 |
| CAS No | NA |
| Mol.F. | C20H24N2O5 |
| Mol.Wt. | 372.42 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143053 |
| CAS No | NA |
| Mol.F. | C16H17N3O4 |
| Mol.Wt. | 315.33 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143054 |
| CAS No | NA |
| Mol.F. | C19H21N3O4 |
| Mol.Wt. | 355.39 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143055 |
| CAS No | NA |
| Mol.F. | C19H22BrN3O4 |
| Mol.Wt. | 436.31 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143056 |
| CAS No | NA |
| Mol.F. | C24H34N4O8 |
| Mol.Wt. | 506.56 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143057 |
| CAS No | NA |
| Mol.F. | C37H52N6O9 |
| Mol.Wt. | 724.86 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143058 |
| CAS No | NA |
| Mol.F. | C8H12F3N3O4 |
| Mol.Wt. | 271.20 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143059 |
| CAS No | NA |
| Mol.F. | C20H26F3N3O6 |
| Mol.Wt. | 461.44 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |